December 2007
Worldwide Biotech;Dec2007, Vol. 19 Issue 12, p8
Trade Publication
The article reports that topline overall survival results for the double-blinded, randomized satraplatin Phase 3 registrational trial, the Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial, has been announced by GPC Biotech AG and PharmionCorporation. The trial evaluated satraplatin plus prednisone versus placebo plus prednisone. It is intended as a second-line treatment in 950 patients with hormone-refractory prostate cancer (HRPC).


Related Articles

  • A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Paller, C J; Ye, X; Wozniak, P J; Gillespie, B K; Sieber, P R; Greengold, R H; Stockton, B R; Hertzman, B L; Efros, M D; Roper, R P; Liker, H R; Carducci, M A // Prostate Cancer & Prostatic Diseases;Mar2013, Vol. 16 Issue 1, p50 

    Background:Pomegranate juice has been associated with PSA doubling time (PSADT) elongation in a single-arm phase II trial. This study assesses biological activity of two doses of pomegranate extract (POMx) in men with recurrent prostate cancer, using changes in PSADT as the primary...

  • Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. Latte, Jenny; Taverner, David // American Journal of Rhinology;Jul/Aug2007, Vol. 21 Issue 4, p452 

    Background: Single-dose studies indicate that pseudoephedrine (PSE) provides moderate relief for congestion in coryza, but there is a lack of repeated-dose studies. Methods: Two hundred sixteen subjects participated in this double-blind, randomized placebo-controlled trial over 3 days....

  • The Emperor's Sham - wrong assumption that sham needling is sham. Lundeberg, Thomas; Lund, Iréne; Näslund, Jan; Thomas, Moolamanil // Acupuncture in Medicine;Dec2008, Vol. 26 Issue 4, p239 

    During the last five years a large number of randomised controlled clinical trials (RCTs) have been published on the efficacy of acupuncture in different conditions. In most of these studies verum is compared with sham acupuncture. In general both verum and sham have been found to be effective,...

  • Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials. Meissner, Karin; Distel, Hans; Mitzdorf, Ulla // BMC Medicine;2007, Vol. 5, p3 

    Background: Recent reviews on placebo effects in clinical trials suggest that objective changes following placebo treatments may not exist or, at least, have been considerably overestimated. However, the possibility that yet unidentified subsets of parameters are responsive to placebo ...

  • Validation of Placebo in a Manual Therapy Randomized Controlled Trial. Chaibi, Aleksander; Bjørn Russell, Michael; Šaltytė Benth, Jūratė // Scientific Reports;7/10/2015, p11774 

    At present, no consensus exists among clinical and academic experts regarding an appropriate placebo for randomized controlled trials (RCTs) of spinal manipulative therapy (SMT). Therefore, we investigated whether it was possible to conduct a chiropractic manual-therapy RCT with placebo. Seventy...

  • A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. Huber, Adam M.; King, Jim; McLaine, Peter; Klassen, Terry; Pothos, Mary // BMC Medicine;2004, Vol. 2, p7 

    Background: Henoch Schönlein Purpura (HSP) is the most common systemic vasculitis of childhood. There is considerable controversy over whether children with HSP should be treated with corticosteroids. The goal of this study was to investigate whether early corticosteroid administration could...

  • Erlotinib in Previously Treated Non—Small-Cell Lung Cancer. Shepherd, Frances A.; Rodrigues Pereira, José; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjak, Andrea; Clark, Gary; Santabárbara, Pedro; Seymour, Lesley // New England Journal of Medicine;7/14/2005, Vol. 353 Issue 2, p123 

    Background: We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. Methods: Patients with...

  • Re: Racial Disparities in Cancer Survival Among Randomized Clinical Trials of the Southwest Oncology Group. GRAVLEE, CLARENCE C.; MULLIGAN, CONNIE J. // JNCI: Journal of the National Cancer Institute;2/24/2010, Vol. 102 Issue 4, p280 

    This section presents comments on the article "Racial Disparities in Cancer Survival Among Randomized Clinical Trials of the Southwest Oncology Group," by Albain et al. The authors claim that the speculations made by Albain et al. about genetic differences go beyond the data and neglect...

  • Clinical Equipoise and the Incoherence of Research Ethics. Miller, Franklin G.; Brody, Howard // Journal of Medicine & Philosophy;Mar/Apr2007, Vol. 32 Issue 2, p151 

    The doctrine of clinical equipoise is appealing because it appears to permit physicians to maintain their therapeutic obligation to offer optimal medical care to patients while conducting randomized controlled trials (RCTs). The appearance, however, is deceptive. In this article we argue that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics